Amgen builds structural damage claims
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen/Wyeth's Enbrel (etanercept) sBLA for "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis" clears FDA Aug. 21. Amgen's interleukin-1 receptor antagonist Kineret (anakinra) also clears FDA Aug. 22 with a supplemental indication for slowing progression of structural damage in moderately to severely active rheumatoid arthritis (1Pharmaceutical Approvals Monthly Nov. 1, 2002, p. 9)...
You may also be interested in...
Amgen Submits Kineret, Enbrel sBLAs; Triangle Files Coviracil NRTI
Amgen’s Kineret Oct. 21 sBLA for a claim to inhibit progression of structural damage in adults with moderately to severely active rheumatoid arthritis is based on a single 12-month, double-blind, placebo-controlled trial.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.